|Written by Rob Goldman|
Well, last week was certainly an improvement, huh? With word that some investment firms specializing in the small cap arena are in the midst of layoffs because small caps remain in a bear market, the road ahead is filled with potholes.
Still, if you look hard enough, there are bargains to be had. We highlight two this week. One is a name we have profiled before and this tech stock trades with a P/E of 8,5x, a 50% discount to its historical and projected growth rates! The other has a penchant for crushing Wall Street EPS forecasts, beating them by an average of 46% for the past four quarters. As luck would have it, this health care company reports financials this week and we think it could enjoy a nice pop if it exceeds estimates.
OBEY THE SIGNS
History has a nasty habit of repeating itself. In the stock market and corporate finance world, investment firms tend to over-hire and then when the going gets tough, they fire at will.
We have seen reports of research analyst and support staff firings for those covering the energy and a number of small cap sectors. Traders are also being let go. Investment bankers are next, if they aren’t in the line of fire already.
All of this means that firms are having difficulty dealing with the lower trading volumes, reduced interest, fewer deals, etc. and more pain is ahead. It is no secret that small caps are out of favor and the market has little conviction, with the road ahead in general a tough one to hoe. Still, there are real ways to make generate positive returns as values abound—if you know where to look.
For example, Orbotech (NASDAQ—ORBK—$20.74), our pick of the year in 2015 and one that has been featured a number of times here over the years, is cheap as hell at current levels. ORBK grew EPS by 41% in 2015 versus 2014, and forecasts suggest an average EPS growth rate of 15% for the next two years. Yet, the stock trades 10x FY15 EPS and only 8.5x FY16E EPS, a 50% discount to its projected growth rate. Clearly, the stock is primed for a 20% gain which would take it to the still cheap 10x EPS level.
An EPS Estimate Crusher
As the chart above illustrates, the bounce of the recent lows has been a nice one, but we have a lot of ground to make up. Still, in addition to growth/value plays, short term trading opportunities exist as well. While greater risk is associated with short term trading activity, the risk is reduced when one elects to trade or invest in shares of companies that have a recent history of crushing Wall Street forecasts.
With this in mind, we have identified LeMaitre Vascular, Inc. (NASDAQ – LMAT - $12.80), a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. LMAT has done a great job of beating quarterly estimates of late. For the past four quarters, LMAT has exceeded Wall Street consensus EPS projections by an average of 46%!
The Company is slated to release 4Q15 financials and considering that heart and vascular disease is the number one health issue for men and women in the U.S, the Company is solidly in position from the demand side. The EPS forecast of $0.09 compares with $0.11 in the prior year and we believe that the stock could enjoy a real pop if they exceed estimates.
Great info, insights, and hard-hitting stories make up this week’s Say What? feature...
Fascinating. Maybe they will start buying small caps now?
The New York Post
Rest assured, this is not the first time regulators “extorted” deals our of businesses.
Best story/headline all week.
Poor market conditions haven’t hurt.
Simplistic but largely accurate, I believe.
The Stock Market Today
AAII Sentiment Survey (figures rounded)
Well, with gains of 3-4% from a week ago, it is easy to see why Bulls rose and the Bears fell. Hopefully, we have gains ahead, albeit it is likely the returns will be muted. Ticker Sense did not yet update its poll but I suspect that changes will be similar. I, for one, will be interested to see if a turn was made last week (or this week for matter) in equity fund outflows, breaking a trend that seems to go back prior to December. Keep an eye out on Lipper on Wednesday for more information on this front.
1498 Reisterstown Road, Suite 286 Baltimore Maryland 21208 Phone: 410.609.7100
Launched in May 2010, The Goldman Guide is a free weekly publication of Goldman Small Cap Research and is written by Founder Rob Goldman with contributions from the GSCR contributor team. This non-sponsored investment newsletter seeks to provide investors with market, economic, political and equity-specific insights via an action-oriented, straight to the point approach. No companies mentioned in this newsletter are current sponsored research clients of the Company or its parent, unless noted, With some exceptions, all companies or investment ideas mentioned in this publication are publicly traded stocks listed either on the NYSE or the NASDAQ. Goldman Small Cap Research members and contributors’ bios, certifications, and experience can be found on our website: www.goldmanresearch.com
This newsletter was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces non-sponsored and sponsored (paid) investment research. Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The Firm’s non-sponsored research publications category, Select Research, reflects the Firm’s internally generated stock ideas, along with economic, industry and market outlooks. In virtually all cases, stocks mentioned in Select Research offerings are listed on the NYSE or the NASDAQ. Publications in this category include the weekly newsletter The Goldman Guide, Market Monitor blogs, Special Reports, and premium products such as The 30-30 Report. Goldman Small Cap Research analysts are neither long nor short stocks mentioned in this newsletter.
Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in company-specific Opportunity Research reports, updates and articles.
Goldman Small Cap Research has not been compensated for any content in this issue.
All information contained in this newsletter and in our reports were provided by the companies mentioned via news releases, filings, and their websites or generated from our own due diligence. Economic, market data and charts are provided by a variety of sources and are cited upon publication. Stock performance data and information are derived from Yahoo! Finance and other websites or sources, as noted. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, other firms, or other financial news outlets. Goldman Small Cap Research relied solely upon information provided by companies through filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, blog, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
Separate from the factual content of our articles about the company featured in this newsletter, we may from time to time include our own opinions about the companies profiled herein, their businesses, markets and opportunities. Any opinions we may offer about the companies are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.